ilmscore | This pharma company spends 15% of revenues on Research!

This pharma company spends 15% of revenues on Research!

Published: 2025-06-01
Status: Analyzed

Predictions from this Video

Total: 3
Correct: 0
Incorrect: 0
Pending: 3
Prediction
Topic
Status
Work Hard aims to make innovation-led product (IPP) revenue the main driver of its portfolio in the next few years.
"The target of work hard is to grow IPP late revenue today over the next few years and make it the driver of the portfolio."
Work Hard Pharma Strategy
Pending
Work Hard's new molecules (WC5 Triple2, 4873, and 67) are predicted to receive regulatory approval within 1 to 3 quarters from the video's publication date (June 2025).
"I think the approval can come any time in the next one to maybe three quarters."
Work Hard Drug Approval
Pending
Work Hard's promising drug molecules (WC5 Triple 2, 4873, and 67) are predicted to receive regulatory approval within 1-3 quarters from June 1, 2025.
"I think the approval can come any time in the next one to maybe three quarters."
Work Hard Pharma - Drug Approval
Pending